Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Fixel-based analysis
Free-water
Longitudinal
Neurite Orientation and Density
Parkinsonism
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
01
2022
revised:
29
03
2022
accepted:
24
04
2022
pubmed:
1
5
2022
medline:
20
5
2022
entrez:
30
4
2022
Statut:
ppublish
Résumé
Advanced diffusion imaging which accounts for complex tissue properties, such as crossing fibers and extracellular fluid, may detect longitudinal changes in widespread pathology in atypical Parkinsonian syndromes. We implemented fixel-based analysis, Neurite Orientation and Density Imaging (NODDI), and free-water imaging in Parkinson's disease (PD), multiple system atrophy (MSAp), progressive supranuclear palsy (PSP), and controls longitudinally over one year. Further, we used these three advanced diffusion imaging techniques to investigate longitudinal progression-related effects in key white matter tracts and gray matter regions in PD and two common atypical Parkinsonian disorders. Fixel-based analysis and free-water imaging revealed longitudinal declines in a greater number of descending sensorimotor tracts in MSAp and PSP compared to PD. In contrast, only the primary motor descending sensorimotor tract had progressive decline over one year, measured by fiber density (FD), in PD compared to that in controls. PSP was characterized by longitudinal impairment in multiple transcallosal tracts (primary motor, dorsal and ventral premotor, pre-supplementary motor, and supplementary motor area) as measured by FD, whereas there were no transcallosal tracts with longitudinal FD impairment in MSAp and PD. In addition, free-water (FW) and FW-corrected fractional anisotropy (FAt) in gray matter regions showed longitudinal changes over one year in regions that have previously shown cross-sectional impairment in MSAp (putamen) and PSP (substantia nigra, putamen, subthalamic nucleus, red nucleus, and pedunculopontine nucleus). NODDI did not detect any longitudinal white matter tract progression effects and there were few effects in gray matter regions across Parkinsonian disorders. All three imaging methods were associated with change in clinical disease severity across all three Parkinsonian syndromes. These results identify novel extra-nigral and extra-striatal longitudinal progression effects in atypical Parkinsonian disorders through the application of multiple diffusion methods that are related to clinical disease progression. Moreover, the findings suggest that fixel-based analysis and free-water imaging are both particularly sensitive to these longitudinal changes in atypical Parkinsonian disorders.
Identifiants
pubmed: 35489192
pii: S2213-1582(22)00087-0
doi: 10.1016/j.nicl.2022.103022
pmc: PMC9062732
pii:
doi:
Substances chimiques
Water
059QF0KO0R
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
103022Subventions
Organisme : NIH HHS
ID : S10 OD021726
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM014027
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS102038
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS058487
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS052318
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Mov Disord. 2018 Nov;33(11):1688-1699
pubmed: 30280416
Mov Disord. 2007 Sep 15;22(12):1771-6
pubmed: 17579357
Mov Disord. 2007 Jan;22(1):41-7
pubmed: 17115387
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
Front Aging Neurosci. 2021 Mar 16;13:625874
pubmed: 33815089
Neuroimage. 2012 Jul 16;61(4):1000-16
pubmed: 22484410
Brain. 2015 Aug;138(Pt 8):2293-309
pubmed: 25981961
Brain. 2005 Oct;128(Pt 10):2272-80
pubmed: 16014651
Brain. 2007 Jun;130(Pt 6):1552-65
pubmed: 17405767
Brain. 2017 Aug 1;140(8):2183-2192
pubmed: 28899020
Neuroimage. 2017 Jan 1;144(Pt A):58-73
pubmed: 27639350
Cereb Cortex. 2018 May 1;28(5):1685-1699
pubmed: 28334314
Neurology. 2016 Aug 16;87(7):709-17
pubmed: 27421545
Cold Spring Harb Perspect Med. 2012 Aug 01;2(8):
pubmed: 22908195
Magn Reson Med. 2009 Sep;62(3):717-30
pubmed: 19623619
Front Neurosci. 2021 Nov 26;15:746214
pubmed: 34899158
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Neurobiol Aging. 2015 Feb;36(2):1097-104
pubmed: 25467638
Mov Disord. 2022 Feb;37(2):325-333
pubmed: 34724257
J Neurosci. 2015 Jan 28;35(4):1753-62
pubmed: 25632148
Mov Disord. 2016 Mar;31(3):325-34
pubmed: 26676922
Mov Disord. 2004 Dec;19(12):1391-402
pubmed: 15452868
Neuroimage. 2016 Nov 15;142:394-406
pubmed: 27523449
Neurology. 2003 Jun 10;60(11):1766-9
pubmed: 12796528
Brain. 2008 Feb;131(Pt 2):460-72
pubmed: 18158316
PLoS One. 2016 Jun 16;11(6):e0157218
pubmed: 27310132
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
JAMA Neurol. 2021 Oct 1;78(10):1262-1272
pubmed: 34459865
Neuroimage. 2011 Jun 1;56(3):1171-80
pubmed: 21316463
Brain. 2015 Aug;138(Pt 8):2322-31
pubmed: 25981960
J Neurol Sci. 2016 Apr 15;363:90-4
pubmed: 27000228
Mov Disord. 2014 Mar;29(3):380-7
pubmed: 24243813
Brain. 1991 Oct;114 ( Pt 5):2283-301
pubmed: 1933245
J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):169-179
pubmed: 34583941
Neurology. 2016 Nov 8;87(19):2016-2025
pubmed: 27742814
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Neuroimage. 2016 Jan 1;124(Pt A):724-732
pubmed: 26385011
Hum Brain Mapp. 2019 Dec 1;40(17):5094-5107
pubmed: 31403737
Neuroimage Clin. 2019;24:102098
pubmed: 31795054
Mov Disord. 1997 Mar;12(2):133-47
pubmed: 9087971
Neurobiol Aging. 2021 May;101:187-198
pubmed: 33631470
Lancet Digit Health. 2019 Sep;1(5):e222-e231
pubmed: 32259098
Neuroimage. 2019 Oct 15;200:302-312
pubmed: 31260838
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Brain. 2011 Aug;134(Pt 8):2248-60
pubmed: 21764818
Med Image Anal. 2008 Feb;12(1):26-41
pubmed: 17659998
Mov Disord. 2021 May;36(5):1191-1202
pubmed: 33421201
Mov Disord. 2019 Jan;34(1):105-113
pubmed: 30468693
Neuroimage. 2012 Feb 15;59(4):3976-94
pubmed: 22036682
Neuroimage Clin. 2020;27:102355
pubmed: 32736325
Brain. 2016 Feb;139(Pt 2):495-508
pubmed: 26705348
Neuroradiology. 2012 Sep;54(9):947-55
pubmed: 22274571
Neuroimage. 2016 Jan 15;125:1063-1078
pubmed: 26481672
Brain. 2006 Oct;129(Pt 10):2679-87
pubmed: 16815875
Brain. 2018 Feb 1;141(2):472-485
pubmed: 29293948
Neuroimage. 2014 Dec;103:411-426
pubmed: 25109526
Mov Disord. 2017 Oct;32(10):1457-1464
pubmed: 28714593
J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):722-8
pubmed: 17353258